Please login to the form below
melanoma
This page shows the latest melanoma news and features for those working in and with pharma, biotech and healthcare.
Checkpoint inhibitor scientists win Nobel Prize
Two years later the antibody – now called Yervoy – was approved by the FDA for melanoma after extending survival in late-stage testing.
Latest news
-
Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
Proactive adjuvant treatment could extend melanoma patient lives. England’s cost effectiveness watchdog NICE has recommended the use of Novartis’Tafinlar (dabrafenib and Mekinst (trametinib) combination in melanoma. ... The decision is a boost for
-
NICE turns down Opdivo for adjuvant melanoma therapy
NICE turns down Opdivo for adjuvant melanoma therapy. BMS drug currently only licensed treatment in this setting. ... surveillance, which is usual current management for completely resected stage III and IV melanoma.”.
-
Boehringer bolts on another immuno-oncology company
approved by the FDA for melanoma in 2015.
-
Novartis wins key adjuvant Taf/Mek approval in Europe
Novartis’cancer combination Tafinlar and Mekinist has been approved by the EMA for adjuvant treatment of advanced melanoma in order to prevent disease recurrence. ... The new indication – the third for the BRAF/MEK inhibitor combination – is an
-
Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar
Will Pfizer spark price war with its Herceptin biosimilar? Eclipsed, but still growing: Opdivo approved in new melanoma setting. ... The European Commission has just approved Opdivo for the adjuvant treatment of adult patients with melanoma with
More from news
Approximately 78 fully matching, plus 284 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Cavatak is now in three trials in melanoma, bladder cancer and NSCLC that are due to generate results in 2018/2019.
-
Communication is the key to unlocking the potential of immuno-oncology
Decades later, in a twist of presidential fate, 92-year old fellow US President Jimmy Carter received his all clear from melanoma thanks in part to an entirely new way to
-
Lighting the way
The independent review's final report emerged in October 2016, with potential implications for treatment access for a number of conditions, with myeloma, melanoma and dementia highlighted in the publication.
-
Managed Access Programmes: a powerful source of real-world insight
Berking C, Bender A, Schneider L, Erik A, Garbe C, Weichenithal M, Schadendorf D, Hauschild A, Mohr POutcome on 560 metastatic melanoma(MM) patients treated with pembrolizumab during the German expanded
-
Managed Access Programmes: a powerful source of real-world insight
Berking C, Bender A, Schneider L, Erik A, Garbe C, Weichenithal M, Schadendorf D, Hauschild A, Mohr POutcome on 560 metastatic melanoma(MM) patients treated with pembrolizumab during the German expanded
More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.
Latest appointments
-
Industry appointments
Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma
-
Packer Forbes appoints Jade McCudden
McCudden has worked across a number of disease areas including hepatitis C, anticoagulation, Alzheimer's disease, women's health, melanoma and nicotine replacement therapy.
-
Array appoints Victor Sandor chief medical officer
This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.
-
Bruno Strigini leaves Merck & Co for Novartis
Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.
-
Chris Bowden joins Agios
During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Why patient education is important in oncology
Why patient education is important in oncology. We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments ... Therefore, the Melanoma Patient Network Europe has a
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
-
Immuno-oncology; bringing patients closer to treatment
Multi-stakeholder immuno-oncology experience. Blue Latitude Health has worked across a number of immunotherapies in melanoma, lung cancer, myeloma and acute lymphoblastic leukaemia.
-
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships
Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
-
A stumble, but not a fall – what’s next for Opdivo?
The immuno-oncology treatment won an accelerated FDA approval for metastatic melanoma in December 2014, and has since proved to be a thriving sensation.
More from PMHub
Approximately 2 fully matching, plus 9 partially matching documents found.
Featured jobs
- Account Director – Global Healthcare PR
-
Salary TBC
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
-
Scientific Director
-
Highly Competitive Salary &Benefits
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
- Experienced Editor, London, Medical Communications
-
Competitive package
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Scientific Team Lead
-
Competitive Salary
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Account Manager, Healthcare Advertising
-
Salary TBC
-
Account Director - Digital
-
Great salary and benefits
- Director Healthcare PR Communications
-
Salary TBC
-
Account Director
-
Negotiable
Subscribe to our email news alerts
- Redefining communications excellence
- AstraZeneca: building a new ‘open innovation’ pharma company
- In conversation with Pfizer’s Erik Nordkamp
- CHMP delays decision on Kiadis’ GVHD immunotherapy
- FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy
- 90TEN boosts PR and medical education teams with senior hires
PMHub
Videum Health
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...
Latest intelligence
- Redefining communications excellence
- How to be heard in today’s multichannel, multistakeholder, multimedia world...
- AstraZeneca: building a new ‘open innovation’ pharma company
- The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
- In conversation with Pfizer’s Erik Nordkamp
- Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...
Quick links
Infographics
